Altimmune Advances Pemvidutide into Phase 3 Trial for MASH Treatment
Event summary
- Altimmune initiated the PERFORMA Phase 3 trial for pemvidutide in MASH patients with moderate to advanced fibrosis.
- The global, placebo-controlled study aims to evaluate fibrosis improvement, MASH resolution, and clinical outcomes.
- Data readout from the 52-week trial is anticipated in 2029.
- Pemvidutide has received Fast Track and Breakthrough Therapy Designations from the FDA for MASH treatment.
The big picture
Altimmune's advancement of pemvidutide into Phase 3 trials marks a critical step in addressing the unmet needs in MASH treatment, a disease affecting millions worldwide. The trial's global scope and regulatory support underscore the potential for pemvidutide to become a key player in managing metabolic dysfunction-associated steatohepatitis, leveraging its unique dual-action mechanism targeting both liver health and metabolic benefits.
What we're watching
- Regulatory Pathway
- Whether the Fast Track and Breakthrough Therapy Designations will accelerate pemvidutide's approval process.
- Clinical Efficacy
- How the Phase 3 trial results compare to the positive Phase 2b data, particularly in fibrosis improvement and MASH resolution.
- Market Differentiation
- The pace at which pemvidutide can establish itself as a differentiated therapy in the competitive MASH treatment landscape.